RecruitingPhase 2

A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis

China222 participantsStarted 2026-01-16

Plain-language summary

This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. The target population is patients with active psoriatic arthritis. A total of 222 subjects are planned to be included.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Subjects voluntarily take part in the study after being fully informed, sign a written informed consent form (ICF), and agree to follow procedures specified in the study protocol;
✓. Males and females, 18 to 70 years of age, inclusive at the time of signing of ICF;
✓. Have had an psoriatic arthritis of ≥ 3 months in duration prior to signing of ICF;
✓. Have had active arthritis, characterized by at least ≥3 tender joints (68 joint tenderness counts) and ≥3 swollen joints (66 joint swelling counts).

Exclusion criteria

✕. History of infection as defined in the protocol;
✕. Any of the medical diseases or disorders listed in the protocol;
✕. Significant, uncontrolled or unstable disease in any organ.

What they're measuring

Proportion of subjects achieving ACR20 at Week 12 of treatment.

Timeframe: Week 12

Trial details

NCT IDNCT07315061

SponsorInventisBio Co., Ltd

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2027-08-15

Contact for this trial

yi liu, Dr.

13401466347 zhongchen.ma@inventisbio.com

View on ClinicalTrials.gov More PsA (Psoriatic Arthritis) trials